Prime Medicine (PRME) Net Cash Flow (2021 - 2026)

Prime Medicine (PRME) has 6 years of Net Cash Flow data on file, last reported at $1.1 million in Q1 2026.

• Quarterly Net Cash Flow rose 101.19% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.1 million (down 1537.11% YoY) and the FY2025 annual result came in at -$119.8 million, down 184.69% from the prior year.
• Net Cash Flow grew to $1.1 million in Q1 2026, from -$8.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $139.7 million in Q4 2022 to a low of -$90.6 million in Q1 2025.
• A 5-year average of -$7.1 million and a median of -$12.9 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 6691.46% — and 2025, when it sank 272.28%.
• Tracing PRME's Net Cash Flow over 5 years: stood at $139.7 million in 2022, then sank by 101.71% to -$2.4 million in 2023, then jumped by 2804.36% to $64.5 million in 2024, then plunged by 112.97% to -$8.4 million in 2025, then soared by 112.84% to $1.1 million in 2026.
• The last three Net Cash Flow figures came in at $1.1 million (Q1 2026), -$8.4 million (Q4 2025), and $17.6 million (Q3 2025), per Business Quant data.